SELLAS Life Sciences Group And 3D Medicines Engaged In Dispute Regarding, Among Other Things, Trigger & Payment Of Milestone Payments; Regarding Failure To Use Commercially Reasonable Best Efforts To Develop GPS In Licensed Territory Particularly China
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group is in a dispute with 3D Medicines over milestone payments and the alleged failure to exert commercially reasonable best efforts to develop GPS in the licensed territory, particularly China, according to an SEC filing.
December 22, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
SELLAS Life Sciences Group is involved in a legal dispute with 3D Medicines concerning milestone payments and development commitments in China, which could affect the company's financials and partnerships.
The dispute between SELLAS and 3D Medicines could lead to financial uncertainties and potential delays in development, which are likely to negatively impact investor sentiment and SLS's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100